Breast magnetic resonance imaging for screening high-risk women.
Mammography is the only imaging modality that has been validated by multiple randomized clinical trials and meta-analyses to reduce mortality from breast cancer. Although it is demonstrated to be effective in reducing mortality from breast cancer, mammography has its limitations, especially in young high-risk women with dense breasts. Other imaging modalities have been pursued as an adjunct screening modality in this population. Of these, the most widely accepted is contrast-enhanced breast magnetic resonance (MR) imaging. This article reviews current recommendations and limitations of using MR imaging of the breast to screen asymptomatic women at high risk for breast cancer.
Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA. sungj@mskcc.org
Janice S
JS
Sung
D David
DD
Dershaw
D019313:BRCA1 Protein / Q000235:genetics*; D024682:BRCA2 Protein / Q000235:genetics*; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000235:genetics*; D055088:Early Detection of Cancer / Q000706:statistics & numerical data*; D019317:Evidence-Based Medicine; D005260:Female; D020022:Genetic Predisposition to Disease / Q000453:epidemiology / Q000235:genetics*; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000706:statistics & numerical data*; D015995:Prevalence; D015203:Reproducibility of Results; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D016387:Women's Health
D019313:BRCA1 Protein; C492913:BRCA1 protein, human; D024682:BRCA2 Protein; C551750:BRCA2 protein, human
BRCA; Cancer; Genetic; Hodgkin; Lymphoma; Risk